Trio Pharmaceuticals
Biotechnology, Bernardo Plaza Dr, San Diego, , 92128, California, 11956, United States, 11-50 Employees
Phone Number: 61********
Who is TRIO PHARMACEUTICALS
We are a cancer therapeutics company with a mission to improve efficacy, reduce toxicity and increase treatment affordability of cancer drugs. We are an experienced team in cancer drug di...
Read More
-
Headquarters: 11956 Bernardo Plaza Dr, San Diego, California, 92128, United States
-
Date Founded: 2018
-
Employees: 11-50
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from TRIO PHARMACEUTICALS
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding TRIO Pharmaceuticals
Answer: TRIO Pharmaceuticals's headquarters are located at Bernardo Plaza Dr, San Diego, , 92128, California, 11956, United States
Answer: TRIO Pharmaceuticals's phone number is 61********
Answer: TRIO Pharmaceuticals's official website is https://triopharmaceuticals.com
Answer: TRIO Pharmaceuticals's revenue is $50 Million to $100 Million
Answer: TRIO Pharmaceuticals's SIC: 2834
Answer: TRIO Pharmaceuticals's NAICS: 325412
Answer: TRIO Pharmaceuticals has 11-50 employees
Answer: TRIO Pharmaceuticals is in Biotechnology
Answer: TRIO Pharmaceuticals contact info: Phone number: 61******** Website: https://triopharmaceuticals.com
Answer: We are a cancer therapeutics company with a mission to improve efficacy, reduce toxicity and increase treatment affordability of cancer drugs. We are an experienced team in cancer drug discovery and development. Team members have invented and developed drugs that are approved for cancer treatment. Our approach to eradicating cancer is distinct from the current standard of care. Current approaches involve single agent single action drugs that either inhibit cancer cell growth or inhibit immunosuppression, and hence, they are ineffective. These drugs are combined in a bid to improve efficacy. But combination leads to toxicity, poor efficacy, and high cost. We are developing single agent dual action treatments inhibiting both cancer growth and immunosuppression. We are not targeting the immune checkpoint axis. Our approach will be effective for cancer patients that failed immune checkpoint treatments due to resistance or low expression of PD1, PDL1, CTLA4 etc..
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month